公开(公告)号：US20140242073A1

公开(公告)日：2014-08-28

申请号：US14240267

申请日：2012-08-10

申请人： Takami Matsuyama ,  Taku Nagai

发明人： Takami Matsuyama ,  Taku Nagai

IPC分类号： C07K16/28 ,  A61K38/16 ,  A61K39/395 ,  C07K14/21

CPC分类号： C07K16/28 ,  A61K47/6829 ,  A61K47/6849 ,  A61K2039/505 ,  C07K14/21 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73

摘要： An object of the present invention is to provide a cartilage/bone destruction suppressor which can suppress the destruction of cartilage or bone seen in rheumatoid arthritis, osteoarthritis, bone metastasis of malignant tumor, or the like. The present invention relates to a cartilage or bone destruction suppressor comprising an antibody against folate receptor β or a complex of the antibody and a biologically or chemically active substance.

摘要翻译： 本发明的目的是提供一种能够抑制类风湿性关节炎，骨关节炎，恶性肿瘤的骨转移等软骨或骨的破坏的软骨/骨破坏抑制剂。 本发明涉及包含抗叶酸受体抗体的抗体的软骨或骨破坏抑制剂。 或抗体与生物或化学活性物质的复合物。

公开(公告)号：US20140010756A1

公开(公告)日：2014-01-09

申请号：US14006048

申请日：2012-03-16

申请人： Sonshin Takao ,  Takami Matsuyama

发明人： Sonshin Takao ,  Takami Matsuyama

IPC分类号： A61K47/48 ,  A61K38/16

CPC分类号： C07K16/28 ,  A61K38/164 ,  A61K39/3955 ,  A61K47/6829 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6859 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/34 ,  C07K2317/624 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/55 ,  G01N33/57438 ,  G01N2333/705

摘要： This invention relates to a pharmaceutical composition for inhibiting the growth and/or metastasis of invasive pancreatic cancer in a subject, comprising a molecular-targeted anticancer agent and a pharmaceutically acceptable carrier, wherein the molecular-targeted anticancer agent is a conjugate of a toxin or cytotoxic agent and an antibody or fragment thereof which immunologically and specifically binds to a cell-surface folate receptor β (FRβ) protein of an FRβ (+) macrophage that exists around pancreatic cancer cells at the invasive front, and to a diagnostic agent and kit for determining the degree of malignancy of pancreatic cancer or the presence of invasive pancreatic cancer, characterized by determining that the cancer tissue is invasive and metastatic when FRβ (+) macrophage is distributed around pancreatic cancer cells at the invasive front.

摘要翻译： 本发明涉及一种用于抑制受试者的侵袭性胰腺癌的生长和/或转移的药物组合物，其包含分子靶向抗癌剂和药学上可接受的载体，其中所述分子靶向抗癌剂是毒素或 细胞毒性剂和抗体或其片段，其免疫和特异性结合存在于侵入性前端的胰腺癌细胞周围的FRbeta（+）巨噬细胞的细胞表面叶酸受体β（FRbeta）蛋白，以及诊断剂和试剂盒 用于确定胰腺癌的恶性程度或侵袭性胰腺癌的存在，其特征在于当FRbeta（+）巨噬细胞分布在侵入性前端的胰腺癌细胞周围时，确定癌组织是侵袭性的和转移的。

公开(公告)号：US20130230899A1

公开(公告)日：2013-09-05

申请号：US13884215

申请日：2011-11-08

申请人： Chuwa Tei ,  Masaaki Miyata ,  Yuko Furusyo ,  Takami Matsuyama ,  Taku Nagai

发明人： Chuwa Tei ,  Masaaki Miyata ,  Yuko Furusyo ,  Takami Matsuyama ,  Taku Nagai

IPC分类号： A61K47/48 ,  G01N33/82 ,  C07K16/28

CPC分类号： A61K47/48561 ,  A61K47/6849 ,  A61K49/0058 ,  C07K16/28 ,  G01N33/82

摘要： It is intended to ameliorate arteriosclerosis or arteriosclerotic disease through a pharmacological mechanism that reduces the size of the arteriosclerotic lesion. The agent of the present invention comprises a complex comprising an antibody binding to folate receptor β (FRβ) and a cytotoxin or a cytotoxic agent conjugated with the antibody, or the antibody as an active ingredient.

摘要翻译： 旨在通过降低动脉硬化病变大小的药理机制来改善动脉硬化或动脉硬化疾病。 本发明的药剂包含包含与叶酸受体β（FRbeta）结合的抗体和与抗体缀合的细胞毒素或细胞毒性剂或作为活性成分的抗体的复合物。

公开(公告)号：US20080260812A1

公开(公告)日：2008-10-23

申请号：US11587923

申请日：2005-04-25

申请人： Takami Matsuyama ,  Ryusaku Nagayoshi ,  Yasuhiro Tsuneyoshi ,  Taku Nagai ,  Kakushima Matsushita

发明人： Takami Matsuyama ,  Ryusaku Nagayoshi ,  Yasuhiro Tsuneyoshi ,  Taku Nagai ,  Kakushima Matsushita

IPC分类号： A61K9/127 ,  C07K16/18 ,  C07H21/00 ,  A61P19/00 ,  A61K39/395 ,  C12N11/00

CPC分类号： C07K16/3061 ,  A61K2039/505 ,  C07K2317/73

摘要： An objective of the present invention is to provide a therapeutic agent for treating rheumatoid arthritis, juvenile rheumatoid arthritis, macrophage activation syndrome, septicemia, and FR-β expressing leukemia, which induces apoptosis in activated macrophages and folate receptor beta (FR-β) expressing leukemia cells to specifically destroy these cells. An FR-β monoclonal antibody of the present invention is preferably an IgG-type monoclonal antibody which specifically reacts with a human-type FR-β antigen and is produced from a clone resulting from immunization with an FR-β expressing B300-19 cell. The FR-β monoclonal antibody of the present invention specifically reacts with the FR-β antigen of activated macrophages and FR-β expressing leukemia cells and a therapeutic agent of the present invention contains an FR-β antibody immunotoxin which causes apoptosis in activated macrophages and FR-β expressing leukemia cells, as an active ingredient. Further, suitable administration form for the therapeutic agent of the present invention includes intravenous injection as well as joint injection in the case of therapeutic agents for rheumatoid arthritis and juvenile arthritis.

摘要翻译： 本发明的目的是提供一种用于治疗类风湿性关节炎，幼年类风湿性关节炎，巨噬细胞活化综合征，败血症和表达FR-β的白血病的治疗剂，其诱导活化的巨噬细胞和叶酸受体β（FR-β）表达的细胞凋亡 白血病细胞特异性地破坏这些细胞。 本发明的FR-β单克隆抗体优选为与人类FR-β抗原特异性反应的IgG型单克隆抗体，并且由用表达B300-19细胞的FR-β免疫接种的克隆产生。 本发明的FR-β单克隆抗体与活化的巨噬细胞和FR-β表达白血病细胞的FR-β抗原特异性反应，本发明的治疗剂含有引起活化的巨噬细胞凋亡的FR-β抗体免疫毒素， FR-β表达白血病细胞作为活性成分。 此外，本发明的治疗剂的合适的给药形式包括静脉注射以及在用于类风湿性关节炎和幼年型关节炎的治疗剂的情况下的联合注射。